Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Patrick Arcement

Physician Assistant Denham Springs, LA Physician Assistant

NPI 1447705835 CMS profile 11233203

139 Veterans Blvd, Denham Springs, LA 70726

Open in the dashboard

General payments

$1,512

64 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Patrick Arcement of Denham Springs, LA is reported in the CMS Open Payments database as having received $1,512 across 64 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $274 8
2024 General $230 11
2023 General $473 14
2022 General $195 10
2021 General $341 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Arcement
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Patrick Arcement were reported at $274. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Patrick Arcement Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $341 $132 $37–$438 $132
2022 $195 $155 $48–$522 $149
2023 $473 $167 $52–$557 $160
2024 $230 $178 $55–$600 $164
2025 $274 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $446 17 payments
  2. Abbott Laboratories $312 22 payments
  3. SI-BONE, Inc. $163 4 payments
  4. Medtronic, Inc. $150 2 payments
  5. Pacira Pharmaceuticals Incorporated $99 6 payments
  6. Flexion Therapeutics, Inc. $83 4 payments
  7. Globus Medical, Inc. $54 2 payments
  8. Kerecis Limited $51 1 payment
  9. DePuy Synthes Sales Inc. $41 1 payment
  10. Integrity Implants Inc $37 1 payment
  11. Other $77 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,512 64 payments
Products named General payments · program years 2021–2025
  1. UNID_PASS $150 2 payments
  2. Proclaim XR IPG $139 11 payments
  3. Exparel $99 6 payments
  4. Zilretta $83 4 payments
  5. PROCLAIM Neuromodulation $74 5 payments
  6. General - Pain Management $72 4 payments
  7. PROCLAIM Neuromodulation $70 4 payments
  8. CREO $54 2 payments
  9. Kerecis Omega3 SurgiClose $51 1 payment
  10. Kerecis Omega3 GraftGuide $51 1 payment
  11. Other $450 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

396

Median for Physician Assistant: 241

Drug cost

$2,804

Median for Physician Assistant: $4,110

Branded share of claims

31.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 69 $770
Methocarbamol Generic 97 $627
Methylprednisolone Generic 51 $302
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 34 $243
Cyclobenzaprine Hcl Generic 38 $218
Ondansetron Odt Ondansetron Brand 12 $158
Gabapentin Generic 21 $115
Tizanidine Hcl Generic 11 $109
Baclofen Generic 12 $75
Meloxicam Generic 23 $69

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$16,962

Of which drugs: $96

Medicare patients

200

Average age 72

Services billed

1,034

120 women, 80 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 35%
Ischemic heart disease 33%
Depression 30%
Chronic kidney disease 27%
Osteoporosis 18%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 14 560 $59
Injection, ketorolac tromethamine, per 15 mg J1885 Office 18 36 $20

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

64 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record